Bob Oliver
CIK 1694534 · last filed 2026-05-29
Bob Oliver is a corporate insider who has filed 10 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for EXEL, was dated May 29, 2026. Across all open-market trades the lifetime net is −$2.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
EXEL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1851 HARBOR BAY PKWY
ALAMEDA, CA 94502
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EXEL | Director | 29,487 | $64.58 | $1.90M | -$2.02M | 7 | 2026-05-29 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | — | — | — | $0 | 1 | 2017-01-12 |
Recent Filings
10 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-29 | EXEL | Grant (A) | +8,367 | $0 | EDGAR |
| 2026-02-18 | EXEL | Mixed | −21,162 | -$1.15M | EDGAR |
| 2026-02-13 | EXEL | Notice (144) | −30,250 | -$1.33M | EDGAR |
| 2025-11-19 | EXEL | Gift (G) | −1,044 | $0 | EDGAR |
| 2025-05-30 | EXEL | Grant (A) | +9,812 | $0 | EDGAR |
| 2025-02-26 | EXEL | Mixed | −3,500 | -$402.6K | EDGAR |
| 2025-02-25 | EXEL | Notice (144) | −18,647 | -$694.6K | EDGAR |
| 2024-06-04 | EXEL | Grant (A) | +18,838 | $0 | EDGAR |
| 2023-06-02 | EXEL | Grant (A) | +18,176 | $0 | EDGAR |
| 2017-01-12 | IMMUNOMEDICS INC (IMMU) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.